Aura Biosciences, Inc. financial data

Symbol
AURA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
80 Guest Street, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 24, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.51K % -16.9%
Debt-to-equity 15.7 % +4.11%
Return On Equity -47.8 % -13.3%
Return On Assets -41.3 % -12.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 50.2M shares +1.46%
Common Stock, Shares, Outstanding 50M shares +1.31%
Entity Public Float 192M USD -14.6%
Weighted Average Number of Shares Outstanding, Basic 49.7M shares +25.3%
Weighted Average Number of Shares Outstanding, Diluted 49.7M shares +25.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 73.3M USD +12.4%
General and Administrative Expense 22.8M USD +15.5%
Operating Income (Loss) -96.1M USD -13.1%
Nonoperating Income (Expense) 9.31M USD +6.76%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -86.8M USD -13.8%
Income Tax Expense (Benefit) 43K USD
Net Income (Loss) Attributable to Parent -86.9M USD -13.8%
Earnings Per Share, Basic -1.75 USD/shares +9.33%
Earnings Per Share, Diluted -1.75 USD/shares +9.33%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 31.7M USD -22.8%
Cash, Cash Equivalents, and Short-term Investments 149M USD +33.7%
Other Assets, Current 1.83M USD -24.2%
Assets, Current 161M USD -30.7%
Property, Plant and Equipment, Net 3.22M USD +2.06%
Operating Lease, Right-of-Use Asset 17.4M USD -7.82%
Other Assets, Noncurrent 518K USD +1.77%
Assets 183M USD -28.5%
Accounts Payable, Current 2.3M USD +28.9%
Liabilities, Current 14.9M USD +20.7%
Operating Lease, Liability, Noncurrent 15.6M USD -7.41%
Liabilities 30.5M USD +4.47%
Accumulated Other Comprehensive Income (Loss), Net of Tax 263K USD -51.2%
Retained Earnings (Accumulated Deficit) -374M USD -30.3%
Stockholders' Equity Attributable to Parent 152M USD -32.7%
Liabilities and Equity 183M USD -28.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -24.5M USD -49%
Net Cash Provided by (Used in) Financing Activities 253K USD +25.9%
Net Cash Provided by (Used in) Investing Activities 9.4M USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 50M shares +1.31%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -14.8M USD +82.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 32.5M USD -22.4%
Deferred Tax Assets, Valuation Allowance 106M USD +29.2%
Deferred Tax Assets, Gross 111M USD +27.4%
Operating Lease, Liability 18.8M USD -4.03%
Depreciation 1.22M USD -5.56%
Payments to Acquire Property, Plant, and Equipment 88K USD -19.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -87.2M USD -15%
Lessee, Operating Lease, Liability, to be Paid 27.7M USD -9.26%
Property, Plant and Equipment, Gross 9.2M USD +12.4%
Operating Lease, Liability, Current 3.15M USD +17.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.41M USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.31M USD +17.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 8.88M USD -18.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.51M USD +3.03%
Deferred Tax Assets, Operating Loss Carryforwards 55.8M USD +21.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.61M USD +2.97%
Operating Lease, Payments 751K USD -2.21%
Additional Paid in Capital 526M USD +2.6%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 11.7M USD +33.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%